Arrowhead Pharmaceuticals (ARWR)
Quick facts
| Ticker | ARWR (NASDAQ) |
|---|
Marketed products
- Redemplo · Metabolic
Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Arrowhead Pharmaceuticals
What is the ticker symbol for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals trades as ARWR on the NASDAQ.
What are Arrowhead Pharmaceuticals's marketed drugs?
Top marketed products include Redemplo.
How many employees does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has approximately 711 employees.
Related
- Redemplo · Metabolic
- Sector hub: All tracked pharma companies
- Ticker: ARWR · NASDAQ